Advertisement

SpringLeaf Therapeutics Inc., a Boston-based maker of combination drug delivery device/therapeutic products, came out of stealth mode today with a $15 million Series B financing that it will use to meet product development milestones, the company said.

The round was led by new investor SR One, the venture capital arm of GlaxoSmithKline, which joins existing investors Flybridge Capital Partners and North Bridge Venture Partners. In conjunction with the financing, Brian M. Gallagher, Jr., partner at SR One, will join SpringLeaf’s board of directors. Flybridge and North Bridge backed the $12 million Series A round in November 2008.

SOURCE

Advertisement
Advertisement